‘No Simple Formula’: US FDA Decisions On Surrogate Endpoints Are Complex, Case-Specific

 
• By Sue Sutter
Math formulas
The FDA has no simple formula for determining whether a surrogate endpoint is reasonably likely to predict clinical benefit. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards